Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

Stock Information for Oragenics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oragenics Inc.

Oragenics, Inc. Files 10K and Provides Company Update
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics Announces Closing of Public Offering
Oragenics Announces Pricing of Public Offering
Oragenics Announces Proposed Public Offering
Oragenics, Inc. Announces Leadership Transition
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.